IDYA Stock Overview
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IDEAYA Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.62 |
| 52 Week High | US$47.74 |
| 52 Week Low | US$14.33 |
| Beta | 0.80 |
| 1 Month Change | -15.10% |
| 3 Month Change | -8.31% |
| 1 Year Change | 158.38% |
| 3 Year Change | 92.43% |
| 5 Year Change | n/a |
| Change since IPO | 236.19% |
Recent News & Updates
Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22
Ideaya Biosciences: A Strong Bet In Targeted Oncology
Feb 16Recent updates
Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22Ideaya Biosciences: A Strong Bet In Targeted Oncology
Feb 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
Nov 09Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Oct 03IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans
Jul 04We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Mar 10Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Nov 04Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
Oct 06Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering
Sep 14Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials
Aug 29Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%
Aug 25IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M
Aug 15IDEAYA, Amgen in clinical trial deal for small molecule cancer agent
Jul 27Ideaya: Next 6 Months Critical For Precision Oncology Biotech
Jun 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
May 16We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth
Apr 12IDEAYA Biosciences EPS beats by $0.01, misses on revenue
May 10If You Had Bought IDEAYA Biosciences (NASDAQ:IDYA) Shares A Year Ago You'd Have Earned 181% Returns
Mar 02Shareholder Returns
| IDYA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.4% | -4.7% | -3.7% |
| 1Y | 158.4% | -2.7% | 20.2% |
Return vs Industry: IDYA exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: IDYA exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| IDYA volatility | |
|---|---|
| IDYA Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IDYA's share price has been volatile over the past 3 months.
Volatility Over Time: IDYA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 124 | Yujiro Hata | www.ideayabio.com |
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
IDEAYA Biosciences, Inc. Fundamentals Summary
| IDYA fundamental statistics | |
|---|---|
| Market cap | US$2.80b |
| Earnings (TTM) | -US$112.96m |
| Revenue (TTM) | US$23.39m |
119.9x
P/S Ratio-24.8x
P/E RatioIs IDYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDYA income statement (TTM) | |
|---|---|
| Revenue | US$23.39m |
| Cost of Revenue | US$129.51m |
| Gross Profit | -US$106.12m |
| Other Expenses | US$6.84m |
| Earnings | -US$112.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.52 |
| Gross Margin | -453.81% |
| Net Profit Margin | -483.05% |
| Debt/Equity Ratio | 0% |
How did IDYA perform over the long term?
See historical performance and comparison